In a recent study, GDC-0941 and siRNA therapeutics targeting KRAS (siKRAS) have been combined to test their synergistic anti-tumor effect in ovarian cancer cell lines and in an allograft ovarian cancer model harboring KRAS mutations. Here, KRAS is linked to ovarian carcinoma.